Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot study

PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirth, Magdalena A., Becker, Matthias D., Graf, Nicole, Michels, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088487/
https://www.ncbi.nlm.nih.gov/pubmed/27847638
http://dx.doi.org/10.1186/s40942-016-0045-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088487/
https://www.ncbi.nlm.nih.gov/pubmed/27847638
http://dx.doi.org/10.1186/s40942-016-0045-8

Ejemplares similares